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The hypothalamic-pituitary-adrenal (HPA) axis functions through a complex set of 
interactions between the hypothalamus, the pituitary and the adrenal glands. It is 
our central stress response system which is activated during physically or mentally 
challenging situations. Activation of the system causes the hypothalamus to secrete 
corticotrophin releasing hormone (CRH). When CRH binds to CRH receptors on the 
anterior pituitary gland, adrenocorticotropic hormone (ACTH) is released by the pitu-
itary. ACTH stimulates the secretion of cortisol by the adrenal cortex. Cortisol, in turn, 
exerts inhibitory effects to the hypothalamus and the pituitary via a negative feedback 
loop (Figure 1). Cortisol secretion shows strong diurnal variation with the lowest 
levels at around midnight, an initiation of the rise at approximately 02.00–03.00 h and 
peak values in the morning directly after waking. Thereafter, levels slowly decrease 
throughout the day until the nadir at midnight.
Besides being activated during stressful situations, the HPA axis is also vital for sup-
porting normal physiological functioning. Cortisol serves several functions in the body 
like the regulation of blood glucose, suppression of the immune system and assistance 
in fat, protein and carbohydrate metabolism.
ADRENAL INSUFFICIENCY
Patients with adrenal insufficiency (AI) are characterized by the loss of endogenous 
cortisol production. This lack of cortisol production can be caused by loss of function 
of the adrenal gland itself, in which case it is called primary AI (PAI) (Figure 1). This 
form of AI is most frequently caused by autoimmune adrenalitis (Addison’s disease) 
or by a disturbed function of one of the enzymes involved in cortisol synthesis (con-
genital adrenal hyperplasia).1,2 AI can also be caused by impairment of the pituitary 
(secondary AI (SAI)) or hypothalamus (tertiary AI), resulting in a deficiency of 
ACTH or CRH, respectively, and subsequently a lack of stimulation of the adrenal 
cortex to produce cortisol. Pituitary tumors or treatment of these pituitary tumors, 
by means of pituitary surgery or radiotherapy, are the most frequent causes of SAI.3 
Pituitary tumors can be classified as functioning or non-functioning, depending on 
their hormonal activity. Non-functioning adenomas have no clinical or biochemical 
features of excessive hormonal secretion, whereas functional pituitary adenomas are 
characterized by excessive pituitary hormonal secretion. Other pituitary region tumors, 
such as craniopharyngiomas, meningeomas, germinomas, intrasellar or suprasellar 
metastases as well as traumatic brain injury can also cause SAI.4 The first choice of 
treatment of pituitary (region) tumors is surgical resection of the tumor, usually via 
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 Figure 1. The hypothalamus-pituitary-adrenal axis during A) the normal physiological situation, 




the transsphenoidal route. It is a minimally invasive technique in which the tumor is 
approached through the nose and sphenoid sinus. Less commonly, when the tumor 
is large or is not accessible through the transsphenoidal route, transcranial surgery is 
performed, in which a section of the skull is removed in order to access the brain. In 
some cases additional radiotherapy is applied, for instance when the tumor is not fully 
resected, when the tumor is recurring or in case of secreting adenomas where hormonal 
control cannot be achieved after surgery and medical therapy.
SAI is a rare disease, it has an estimated prevalence of 150–280 per million.3,5–7 
Patients with untreated SAI present with weight loss, anorexia or loss of appetite, 
generalized fatigue, loss of energy, reduced muscle strength, and increased irritability.4 
However, presenting signs and symptoms are often subtle and unspecific, impeding the 
diagnosis which often leads to a delay in diagnosis.
Diagnosis
The diagnosis of SAI is based on the finding of low early morning cortisol levels. 
Furthermore, in case of indeterminate cortisol values, various stimulation tests are 
available to assess the integrity of the HPA axis. For instance, the ACTH stimulation 
test, also known as the short synacthen test, has been advocated by several investiga-
tors in cases with a suspected disease duration of at least one month. This test can be 
done at any time of the day. Serum cortisol levels are measured at baseline and 30 or 60 
minutes after the administration of 250 µg ACTH. Cortisol responses below 500–550 
nmol/L (specific cut-off values can vary, depending on the assay used for the measure-
ment of cortisol) are indicative of AI. However, when performed within 4 weeks after 
pituitary surgery, the adrenal glands are not yet atrophied and thus may still respond to 
ACTH, wrongly indicating intact HPA axis.
Therefore, the insulin tolerance test is the gold standard for the diagnosis of SAI. In 
this test, a hypoglycemic state is provoked by the administration of 0.1 units of insulin/
kg body weight. Hypoglycemia is a powerful stressor that stimulates the HPA axis.8 
Cortisol concentrations in response to the insulin tolerance test below 500 nmol/L are 
considered to indicate AI. However, the test is cumbersome, expensive and contraindi-
cated in patients with a history of seizures or cardiovascular diseases.2,9,10
TREATmENT OF SAI
Glucocorticoid substitution treatment
Until corticosteroid replacement became available, AI was a deadly disease. Edward 
Kendall was the first to isolate cortisosterone in 1936 and two years later Leonard 
Simpson first used synthetic deoxycorticosterone acetate in the treatment of Addison’s 
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disease with success.11 However, it was only after the synthesis of cortisone that gluco-
corticoids (GCs) became widely available,12 for which Edward Kendall, Philip Hench 
and Tadeus Reichstein received the Nobel Prize in Physiology or Medicine in 1950.
Patients with AI are treated with GCs, of which oral hydrocortisone (HC) is the 
most commonly used preparation. Traditionally it was recommended to administer 
two-thirds (20 mg) of the substitution dose in the morning and one-third (10 mg) in 
the evening. This dose was based on cortisol production rate estimates in healthy 
individuals of 12–15 mg/m²/day. However, using stable isotope tracers the daily cor-
tisol production rate is currently estimated to be approximately 6–10 mg/m²/day,13,14 
corresponding to total daily doses of 15–20 mg/day. Body weight was found to be an 
important factor in the clearance of HC and therefore a weight-adjusted morning dose 
of 0.12 mg/kg body weight is recommended by some investigators.15 Furthermore, 
thrice-daily dosing resulted in more stable and physiological cortisol levels throughout 
the day compared to twice-daily dosing.16 However, uniform guidelines are lacking, 
resulting in a wide variety of substitution regimens with different doses and number of 
daily doses used in clinical practice.17
Next to the lack of consensus about the dose and dose frequency, agreement about 
how to objectively monitor the adequacy of current GC substitution therapy is also 
absent. Blood sampling is informative only when knowing the time of HC administra-
tion and time of blood sampling. Some clinicians use cortisol day curves,18 but they 
are inconvenient for the patient and time-consuming. Moreover, day curves turned out 
to be unable to discriminate between well-substituted and under- or over-substituted 
patients.19
Urinary free cortisol levels have been used as an overall indicator of the adequacy 
of cortisol substitution therapy.18 However, urinary free cortisol levels are influenced 
by corticosteroid-binding-globulin (CBG) binding capacity. CBG saturates rapid 
after oral HC ingestion, at approximately total cortisol concentrations of 450–550 
nmol/L,20,21 which leads to increases of cortisol in urine. As a result, normal ranges 
for healthy individuals cannot be used in the assessment of urinary cortisol excretion 
during GC substitution. Furthermore, daily fluctuations in cortisol are missed due to 
the nature of this measure.22
Salivary cortisol has been used as an alternative, non-invasive method for monitor-
ing substitution therapy. It has several advantages compared to serum cortisol day 
curves, as it is inexpensive, easy to perform, and can be collected at home. However, 
correlations between salivary cortisol and serum cortisol vary.22–25 Furthermore, in 
remains unclear to what extext salivary cortisol reflects tissue cortisol levels.25–27
In practice, clinical assessment of symptoms potentially suggestive of over- or 
under-treatment is often used. Muscle and joint pain, reduced strength, nausea, fatigue 
and lack of energy are symptoms suggestive of under-replacement, whereas weight 
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gain, new onset abdominal obesity, sleeplessness, hypertension and diabetes may 
indicate over-replacement.19 Under-treatment bears the risk of insufficient cortisol 
supply in the case of severe stress risking an adrenal crisis,4 whereas chronic exposure 
to high cortisol levels is associated with increased mortality,28,29 increased risk for 
cardiovascular diseases,30,31 osteoporosis,32 reduced quality of life (QoL) 33 and cogni-
tive impairment.34
Hydrocortisone treatment and cognition
The brain is a major target area for GCs.35 GCs can easily pass the blood-brain barrier 
and they exert their effect via corticosteroid receptors. There are two types of cortico-
steroid receptors: the mineralocorticoid receptor (MR) and the glucocorticoid receptor 
(GR). GRs are widely expressed throughout the brain with highest densities in regions 
such as the prefrontal cortex and limbic areas including the hippocampus, amygdala, 
thalamus and hypothalamus.36 Data on mapping of MRs in the brain is less consistent, 
but high MR density is found in the hippocampus.37 GCs bind to MRs with a 6–10 
fold greater affinity than to GRs.38 This differential affinity results in differences in 
occupation of the two receptors under different conditions. At basal cortisol levels, 
predominantly MRs are occupied. GRs will be activated additionally to MRs only 
when cortisol levels are high, e.g. at the circadian peak or during stress.39
An association between GCs and cognitive functioning is well described. Both in 
animals and in humans, there is convincing evidence of an inverted “U”-shape relation 
between plasma cortisol levels and cognitive functioning.36,40 This means that very low 
and very high cortisol levels impair information processing and cognition.40,41 Particu-
larly the hippocampus is a major target area for GCs, due to its high density of GRs 
and MRs. Hippocampal functioning is therefore likely to be affected by GC levels. It is 
generally accepted that the hippocampus plays an important role in reactivity to novel 
situations and is essential for learning and memory.42
In healthy individuals, several studies reported decreased memory performance in 
association with higher cortisol levels.34,43–51 The impairing effects of GC excess seem 
to be most pronounced in declarative memory as studies have shown that increases in 
endogenous cortisol levels due to stressful conditions induce impairment in declarative 
memory, but not in non-declarative memory.34,44 Another study showed that the ad-
ministration of 25 mg of cortisone to healthy subjects before retention of a previously 
learned list of nouns impaired delayed recall of those words.43 Immediate recall and 
recognition were not impaired, suggesting that cortisol impaired retrieval specifically. 
In addition, declarative verbal memory performance was decreased after administra-
tion of HC doses resembling cortisol levels during major stress in healthy subject.52
The negative side effects of cortisol excess on cognition have also been shown in 
several patient groups. Patients that were exposed to excessive levels of cortisol, for 
16 Chapter 1
instance due to Cushing’s syndrome, showed deficits in memory, visual and spatial 
information processing, reasoning, language performance, verbal learning and atten-
tion.53–56 On the other hand, patients with hypocortisolism also reported impairments 
in cognitive functioning.57–60 Compared to healthy matched controls, patients with 
Addison’s disease performed worse on memory and executive functioning tasks,57 
selective attention,58 episodic memory and speed of processing,59 and verbal learning.60
Besides being present in the hippocampus, GRs are also widely expressed in the 
prefrontal cortex, a brain structure known to be involved in executive functioning. 
Executive functions are a set of cognitive processes, including attentional control, 
inhibitory control, working memory, cognitive flexibility/set-shifting, reasoning and 
planning. So far, only a few studies focused on the influence of cortisol on prefrontal 
cortex-dependent cognitive functioning and results are inconclusive. McCormick and 
colleagues61 demonstrated a sex-dependent relationship in healthy subjects between 
salivary cortisol levels and the number of perseverative errors, as a measure of cogni-
tive flexibility and set-shifting. In this task, participants had to sort cards according to a 
certain classification rule (for instance color or shape) and feedback was provided after 
each trial whether the classification was right or wrong. After several trials, the rules of 
classification changed and participants had to shift to a new method of classification. 
Perseverative errors were the trials in which the participants gave the same response 
as in the previous trial even though they received feedback that the response was not 
correct. In women, higher cortisol levels were associated with more perseverative er-
rors, and thus less cognitive flexibility and reduced set-shifting, whereas in men higher 
cortisol levels were associated with more cognitive flexibility. In contrast, Newcomer 
and colleagues52 were not able to demonstrate an effect of HC administration on the 
performance on another test of executive functioning (verbal fluency test) in healthy 
subjects.
Besides being a key area for executive functioning, the prefrontal cortex is also 
known to be involved in social cognition and attention.62,63 Social cognition refers 
to how people process, store and apply information about other people and social 
situations. To our knowledge there are no studies examining the effect of cortisol on 
social cognition. With regard to the effects of cortisol on attention, results are also 
inconclusive. A study showed that, compared to a placebo, the administration of 80 mg 
prednisone/day for 5 days to healthy subjects, leading to increased levels of cortisol, 
led to less salient imprinting of meaningful stimuli and may impair selective atten-
tion.64 In contrast, another study did not find impairments in attentional functioning 
in patients with Addison’s disease,59 neither in healthy subjects after dexamethasone 
treatment48 or after HC treatment.52
In conclusion, these results suggest that cognitive functions that are mediated by the 
hippocampus and the prefrontal cortex are affected by cortisol levels. However, most 
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of the studies performed are cross-sectional studies and included healthy individuals. 
It is therefore likely that the intact negative feedback mechanism in healthy individuals 
influenced the results. No studies have been performed so far assessing the effect of the 
administration of different doses of HC treatment on memory, executive functioning, 
attention and social cognition for a substantial period of time in patients treated for 
SAI.
Hydrocortisone treatment and quality of life
Patients who receive GC substitution often report an impaired QoL compared to 
healthy controls,33,65,66 which results in a high number of patients being unable to work 
and receiving disablement pension.66 The reason for this impairment is likely to be 
multifactorial and, among others, inappropriate GC treatment might play a role. The 
pharmacokinetic properties of currently available GC treatment results in over- or 
under-substitution during certain periods of the day. Indeed, retrospective analyses 
revealed that there is a relationship between the daily GC dose and QoL.33,65,66 Hahner 
and colleagues66 showed a reduced subjective health status in patients with chronic AI. 
Patients with SAI exhibited a slightly more impaired subjective health status, particu-
larly in the domains physical functioning and bodily pain, compared to patients with 
PAI, probably due to common concomitant endocrine disorders that accompany SAI. 
Higher doses were associated with a more profound impairment of subjective health 
status. Ragnarsson and colleagues33 confirmed these findings by showing that higher 
HC equivalent doses were associated with more severely impaired QoL in hypopitu-
itary patients. However, there was no difference in QoL between ACTH sufficient and 
ACTH insufficient patients, indicating that other factors also influence QoL. Due to 
the cross-sectional nature of the above mentioned studies, it remains unclear whether 
the impaired QoL was a result of the higher GC dose taken, or that a higher dose was 
prescribed in order to improve the comprised QoL.
To disentangle cause and effect, QoL in relation to GC dose was assessed within a 
few randomized controlled trials. Wichers and colleagues67 performed a small random-
ized double-blind crossover study and found no differences in QoL between the three 
doses (15, 20 or 30 mg HC/day) administered. Furthermore, in another randomized 
open label crossover study no difference in QoL scores between the three doses (15, 20 
and 30 mg HC/day) was found; irrespective of the dose, patients reported significantly 
lower levels of energy compared to healthy controls.68 In another randomized double-
blind crossover study patients showed improvements in physical functioning on the 
lowest HC dose administered (15 mg HC/day) compared to the other regimens (20 mg 
HC/day or 5 mg prednisone/day).69 However, even though QoL improved on the low-
est dose regimen, it remained impaired compared to healthy controls. Furthermore, in 
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accordance with the study by Ragnarsson,33 QoL did not differ from ACTH-sufficient 
patients.
It can thus be concluded that GC substitution treatment appears to have an effect 
on QoL. However, in the abovementioned controlled trials overall sample sizes were 
small, treatment periods were short and in some studies timing of the dosing was 
changed together with the total daily dose, introducing an extra potential influencing 
factor. Furthermore, results are conflicting and the exact relationship between GC dose 
and QoL remains inconclusive.
Hydrocortisone treatment and cardiovascular risk factors
Patients with SAI show an increased mortality rate, predominantly caused by cardio-
vascular and cerebrovascular diseases.7,28 Inadequate substitution therapy with GCs 
might contribute to this increased risk for cardiovascular diseases. In order to prevent 
low levels of cortisol as a consequence of the short half-life of currently available im-
mediate release tablets, patients are administered doses resulting in supraphysiological 
cortisol concentrations after intake. Higher doses of GC substitution treatment are 
associated with increased severity of cardiovascular risk factors. A study in the Scot-
tish population showed that patients receiving exogenous GCs of doses equivalent to 
more than 30 mg HC/day had increased rates of all cardiovascular diseases, including 
myocardial infarction, heart failure and cerebrovascular disease.30 Cardiovascular risk 
in patients exposed to low dose GCs was similar to the risk in patients not receiving 
exogenous GCs.30 Furthermore, a large Scandinavian study in 2424 patients with hy-
popituitarism also demonstrated that higher doses of HC are associated with increased 
cardiovascular risk.17 Hypopituitary patients requiring GC replacement therapy had 
higher waist circumference, hemoglobin A1c, total cholesterol and triglycerides than 
ACTH sufficient patients (i.e. those not requiring GC treatment). Only those receiving 
doses of 20 mg/day or more showed an unfavorable metabolic profile. Moreover, all 
new cases of diabetes, stroke and myocardial infarction occurred in the GC treated 
group.17
High blood pressure is known to be an independent risk factor for cardiovascular 
diseases and hypertension is responsible for approximately 50 % of deaths from stroke 
or cardiovascular disease.70 A few controlled studies have investigated the effect of 
GC dose on blood pressure. Dunne and colleagues71 studied whether a reduction of the 
GC replacement dose would improve cardiovascular parameters in 13 hypopituitary 
patients. A reduction of the dose from 30 mg HC/day to 15 mg HC/day did not alter 
blood pressure values. Furthermore, several other cardiovascular function parameters 
were comparable between patients and a matched control group. Another group studied 
whether an increase in GC dose would alter blood pressure in 17 SAI patients.72 After 
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increasing the HC equivalent dose from < 20 mg/day to 30 mg/day for 7 days, blood 
pressure did not change.
Thus, even though there is a clear relationship between GCs and cardiovascular risk 
factors, the exact effect of GC dose on risk factors and the mechanisms underlying this 
relationship have not yet been fully defined.
Pharmacokinetics of hydrocortisone
The pharmacokinetic properties of oral HC make it difficult to adequately mimic 
the physiological circadian rhythm of cortisol secretion. Oral HC is well absorbed, 
bioavailability is reported to be 96 ± 20 %, indicating complete oral absorption.73 Peak 
levels in plasma are reached at approximately 1.2 h after ingestion and the terminal 
half-life is around 1.8 h.22,73 As mentioned before, a fixed dose of 20 mg in the morning 
and 10 mg in the evening was initially suggested as the standard substitution therapy. 
However, Mah and colleagues15 showed that body weight was an important factor in 
the clearance of HC. Therefore, a weight-adjusted morning dose of 0.12 mg HC/kg 
body weight was recommended as this reduced variability in the maximum cortisol 
concentration, reduced variability in area under the curve and reduced overexposure 
to less than 5 %.15
More than 90 % of circulating cortisol is bound, predominantly to CBG (approxi-
mately 70 %) with high affinity and low capacity and to a lesser extent to albumin 
(approximately 20 %) with low affinity and high capacity.74 This leaves approximately 
2–12 % of free cortisol in the circulation, dependent on the total cortisol concentration. 
Free cortisol is considered the biologically active part of cortisol and can bind to MRs 
and GRs. CBG acts as a reservoir for circulating cortisol.
Several drugs influence cortisol metabolism through altered activity of cytochrome 
P450 3A4 (CYP3A4). Drugs that induce CYP3A4 activity, such as barbiturates, car-
bamazepine, phenytoin, rifampicin, lead to increased metabolism and hence decreased 
cortisol levels, whereas CYP3A4 inhibitors such as arepitant, ketoconazole, ritonavir, 
and diltiazem reduce metabolism and thus increase cortisol levels.75,76
A high inter-individual variability in pharmacokinetic parameters is reported in pa-
tients receiving HC substitution therapy.22,77 Due to the pharmacokinetic properties of 
currently available immediate release tablets, patients are over- or under-treated during 
certain periods of the day.77 Insight into the effect of dose adjustments on pharmacoki-
netic parameters of HC could provide an indication for evaluation and adjustment of 
HC substitution therapy.
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CONSIDERATIONS AND AImS FOR THIS THESIS
Due to the lack of high-quality data underlying current recommendations about treat-
ment of SAI, a randomized controlled trial investigating the effects of HC substitution 
dose in patients with SAI was desirable. This study was designed in 2011–2012 and 
conducted in 2012–2013. Two different doses of HC within the physiological range and 
used in clinical practice were compared. Thrice daily, weight-adjusted dosing before 
food intake, with a morning dose of 0.12 mg HC/kg body weight (with corresponding 
total daily doses of 0.2–0.3 mg HC/kg body weight), was found by other investigators 
to reduce inter-patient variability in maximum cortisol concentrations and this scheme 
was chosen as base for HC substitution in our study.15 However, much higher doses are 
also used in clinical practice,17 and therefore we compared this dose of 0.2–0.3 mg HC/
kg body weight/day to the double amount of it (0.4–0.6 mg HC/kg body weight/day). 
To reduce inter-subject variability, a crossover design was applied in which patients 
were their own controls.
In this study we focussed on the clinical outcome measures cognitive function-
ing, QoL, somatosensory functioning, blood pressure and regulating hormones, and 
pharmacokinetic parameters. As described above, all these variables are known to 
be influenced by cortisol levels and are important parameters in the quality of the 
substitution therapy.
The aim of this thesis is to assess the pathophysiologic effects of these two doses of 
cortisol, and to add evidence for recommendations regarding GC substitution therapy 
in SAI. As described above, we initiated a randomized double-blind crossover study 
(the Supreme Cort study, Clinicaltrials.gov identifier: NCT01546922). This thesis 
describes the results of our study on the effects of two different physiological doses 
of HC with regard to psychological outcome measures (cognition and QoL) as well as 
several somatic outcome measures (somatosensory functioning, blood pressure and 
regulating hormones, and pharmacokinetic parameters).
OUTLINE OF THIS THESIS
This thesis is divided into two parts. The first part focuses on psychological outcome 
measures, the second part describes somatic outcome measures.
The first part consists of the Chapters 2, 3, and 4 and describes the effect of HC 
substitution dose on psychological measures. In Chapter 2 we aimed to evaluate 
whether a lower dose of HC would be beneficial for cognitive functioning. The cog-
nitive domains memory, attention, executive functioning and social cognition were 
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studied. These domains rely on the integrity of brain structures known to be influenced 
by cortisol due to the high density of GRs in these areas.
In Chapter 3 we aimed to evaluate the effect of the two different doses of HC on 
several aspects of health-related QoL. To this end we used validated questionnaires 
assessing QoL at the end of each treatment period as well as the daily assessment of 
somatic complaints, depression, and anxiety by means of diaries.
In Chapter 4 we aimed to assess the mediating role of cortisol levels in the relation-
ship between stress and pain. An individual approach was used in the analysis of a 
relationship between perceived stress, as measured with an anxiety questionnaire, and 
pain, and the mediating role of low cortisol concentrations therein.
The second part consists of Chapters 5, 6, and 7 and describes the effect of HC 
substitution dose on somatic outcomes. In Chapter 5 we aimed to investigate whether 
somatosensory functioning would be affected by treatment with two different doses of 
HC. Detection and pain thresholds were established using mechanical stimuli.
In Chapter 6 we aimed at assessing the effect of HC dose on blood pressure and 
regulating hormones. High doses of GCs are associated with increased cardiovascular 
risk factors including blood pressure. However, the mechanisms underlying this rela-
tionship remain inconclusive. Elaborate laboratory measurements enabled us to also 
explore the underlying mechanisms.
In Chapter 7 we aimed at parameterizing a pharmacokinetic population model of 
HC in patients with SAI. Furthermore, we compared pharmacokinetic properties of 
HC on the two doses of HC for plasma total cortisol, plasma free cortisol and salivary 
cortisol.
Chapter 8 provides the general discussion of the main findings in this thesis and 
addresses future perspectives. In Chapter 9 a summary is given.
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